Drug shows surprising efficacy as treatment for chronic leukemia, mantle cell lymphoma
Both studies, co-led by researchers at the Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC -- James) and at MD Anderson Cancer Center, were published in the Journal's June 19, 2013 online edition.
Chronic Lymphocytic Leukemia and Ibrutinib
Results from this phase Ib/II trial showed an overall response rate (complete and partial) of 71 percent. At 26 months the estimated progression-free survival rate was 75 percent and overall survival was 83 percent.
"Essentially all CLL patients respond well to ibrutinib, which lacks many of the side effects of chemotherapy and frequently produces long-lasting remissions even in patients with high-risk genetic lesions," says study co-leader John C. Byrd, MD, director of the division of hematology and a CLL specialist at the OSUCCC -- James.
CLL is the most common form of leukemia with an estimated 15,000 Americans diagnosed annually. It is a cancer of B cells, which are a major component of the immune system along with T cells. Ibrutinib (PCI-32765) is the first drug designed to target Bruton's tyrosine kinase, a protein essential for CLL-cell survival and proliferation. Ibrutinib kills malignant B cells but has little effect on healthy T cells -- unlike other CLL therapies. This leaves an important arm of the immune system largely intact, enabling patients to remain healthier during treatment.
The trial involved 85 relapsed CLL patients (median age, 66) who took ibrutinib once daily. Fifty-one patients received a 420 mg dose and 34 patients received an 840 mg dose. Long-term therapy was associated with modest side effects such as diarrhea, fatigue, and infection that usually resolved with no treatment delay.
Funding for the study was provided by Pharmacyclics, Inc.; the Leukemia and Lymphoma Society; D. Warren Brown Foundation; Mr. and Mrs. Michael Thomas; the Harry Mangurian Foundation; and the NIH/National Cancer Institute (grant CA140158 and CA095426).
Mantle Cell Lymphoma and Ibrutinib
Results from this phase II trial showed an overall response rate of 68 percent, with 21 percent of patient achieving a complete response and 47 percent achieving a partial response. Estimated overall survival was 58 percent at 18 months.
"This is remarkable because the last agent approved by the Food and Drug Administration for MCL had a 30 percent response rate," says senior author Kristie Blum, MD, associate professor of medicine, and head of the OSUCCC -- James lymphoma program. "This trial suggests that ibrutinib could significantly improve the landscape of therapy options for MCL."
MCL is a type of non-Hodgkin lymphoma, a malignancy that is expected to strike nearly 70,000 Americans in 2013. About 7 percent of those cases will be MCL, a cancer of white blood cells called B lymphocytes, or B cells. Currently, oncologists treat MCL using combination chemotherapy or intensive chemotherapy plus immunotherapy, followed by stem-cell transplantation.
The trial involved 111 patients with relapsed or refractory MCL who took ibrutinib. The trial was conducted at 18 sites. Participants had received one to five prior treatments, which could include the drug bortezomib, an agent sometimes used to treat MCL. The estimated median response duration was 17.5 months and estimated median progression-free survival was 14 months.
Funding for the study was provided by Pharmacyclics, Inc.
Welcome to SUV System Ltd!
SUV System Ltd is ISO 90012008 Certified electronics distributor with 10 years of experiences.
We have built up long term business relationship with about many companies which are stockers and authorized agents. we have a steady and reliable supply to meet customer's demands to the greatest extent .Confidently, we are able to lower your cost and support your business with our years of professional service.
SUV System Ltd is Electronic Components Distributor Supplies,Find Quality Electronic Components Supplies Products IC(Integrated Circuits),Connectors,Capacitor,Resistors,Diodes,Transistors,LED at Suvsystem.com. Sourcing Other Energy, Environment, Excess Inventory Products from Manufacturers and Suppliers at Suvsystem.com
Electronic Components distributor:http://www.suvsystem.com
Connectors Distributor:http://www.suvsystem.com/l/Connectors-1.html
IC Distributor:http://www.suvsystem.com/l/IC(Integrated-Circuits)-1.html
LED Distributor:http://www.suvsystem.com/l/LED-1.html
Capacitor Distributor:http://www.suvsystem.com/l/Capacitor-1.html
Transistor Distributor:http://www.suvsystem.com/l/Transistors-1.html
Resistor Distributor:http://www.suvsystem.com/l/Resistors-1.html
Diode Distributor:http://www.suvsystem.com/l/Diodes-1.html
SUV System Ltd insists on the managing faith ofsincereness,speciality,foresight, win-win,so we build up stable-relationship customers located all over the world, including the States, Europe, Argentina, UAE, Malaysia, Australia,and India etc
we are focus on the following fields,and hope we can help you.
C052C101G2G5CA C052C101G1G5CA C052C101F2G5TA C052C101F2G5CA7301 C052C101F2G5CA C052C100K2R5TA C052C100K2R5CA7301 C052C100K2R5CA C052C100K2G5TA C052C100K2G5CA7301 C052C100K2G5CA C052C100K1G5CA7301 C052C100K1G5CA C052C100J5G5CA7301 C052C100J5G5CA C052C100J2G5CA7301 C052C100J2G5CA C052C100J1G5CA7301 C052C100J1G5CA C052B910J5G5CA C052B822K1X5CA C052B751F5G5CA C052B682K5G5CA C052B681F5G5CA C052B621F5G5CA C052B569C2G5CA C052B561K2X5CA C052B561J5G5CA C052B561J2G5CA C052B519C2G5CA C052C102K5G5CA C052C102K2R5TA7301 C052C102K2R5TA C052C102K2R5CA7301 C052C102K2R5CA C052C102K2G5TA C052C102K2G5CA7301 C052C102K2G5CA C052C102K1R5CA7301 C052C102K1R5CA
http://www.suvsystem.com/a/3019.aspx
